Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin-EIR for prevention of recurrent diverticulitis
NL-OMON48624Phase 2Active, not recruiting
- Sponsor
- Alfasigma
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rifaximin in diverticulitis and diverticular disease, sponsored by Alfasigma. Started Jun 2019; status: active, not recruiting.
02
Drugs
rifaximin
03
Conditions
diverticulitisdiverticular disease
Beyond the preview
Go deeper on NL-OMON48624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48624.